Research Analysts Set Expectations for BIO Q3 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Zacks Research cut their Q3 2027 earnings per share estimates for Bio-Rad Laboratories in a report issued on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $2.39 per share for the quarter, down from their prior forecast of $2.94. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.30 by ($0.04). The business had revenue of $653.00 million during the quarter, compared to analysts’ expectations of $651.30 million. Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

A number of other research firms also recently commented on BIO. Wells Fargo & Company boosted their price objective on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Royal Bank Of Canada lifted their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Citigroup upped their price target on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $304.13 on Friday. The company has a 50-day simple moving average of $303.99 and a 200-day simple moving average of $271.69. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $8.20 billion, a PE ratio of -12.51 and a beta of 1.04. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $373.69.

Insider Activity

In related news, EVP James Barry sold 700 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total value of $214,326.00. Following the sale, the executive vice president owned 510 shares of the company’s stock, valued at approximately $156,151.80. This represents a 57.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 17.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bio-Rad Laboratories

Institutional investors have recently made changes to their positions in the stock. Quent Capital LLC acquired a new stake in shares of Bio-Rad Laboratories during the third quarter valued at $25,000. Caitong International Asset Management Co. Ltd raised its stake in Bio-Rad Laboratories by 3,633.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 109 shares during the last quarter. Quarry LP purchased a new position in Bio-Rad Laboratories in the 1st quarter valued at about $29,000. Farther Finance Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.